KETOROLAC TROMETHAMINE
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- KETOROLAC TROMETHAMINE
- Generic name
- KETOROLAC TROMETHAMINE
- Manufacturer
- PD-Rx Pharmaceuticals, Inc.
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 862dd7b7-8ed5-42bf-870e-a45b86740226
- SPL ID
- 5f66aa68-cb95-e3c9-e063-6294a90a1ea3
- Version
- 13
- Effective date
- 2026-11-03
- Source export date
- 2026-11-13
- Source partition
- 2
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0002-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/3b4204ed830f35b16ab24b2123672d7d93066eb0fd8af1cf09b223d0e4568221/drug-label-0002-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 15:31:52
| Harmonized routes |
|---|
| ORAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | ANDA | 215745 | derived:openfda.application_number |
| application number | ANDA215745 | openfda.application_number | |
| brand name | KETOROLAC TROMETHAMINE | openfda.brand_name | |
| generic name | KETOROLAC TROMETHAMINE | openfda.generic_name | |
| manufacturer name | PD-Rx Pharmaceuticals, Inc. | openfda.manufacturer_name | |
| ndc | package | 72789-437-01 | openfda.package_ndc |
| ndc | package | 72789-437-20 | openfda.package_ndc |
| ndc | package | 72789-437-10 | openfda.package_ndc |
| ndc | product | 72789-437 | openfda.product_ndc |
| ndc11 | package | 72789043701 | derived:openfda.package_ndc |
| ndc11 | package | 72789043710 | derived:openfda.package_ndc |
| ndc11 | package | 72789043720 | derived:openfda.package_ndc |
| rxcui | 834022 | openfda.rxcui | |
| spl id | 5f66aa68-cb95-e3c9-e063-6294a90a1ea3 | id | |
| spl set id | 862dd7b7-8ed5-42bf-870e-a45b86740226 | set_id | |
| unii | 4EVE5946BQ | openfda.unii |
Boxed warning cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNING Ketorolac tromethamine tablets, a nonsteroidal anti-inflammatory drug (NSAID), are indicated for the short-term (up to 5 days in adults), management of moderately severe acute pain that requires analgesia at the opioid level and only as continuation treatment following IV or IM dosing of ketorolac tromethamine, if necessary. The total combined duration of use of ketorolac tromethamine tablets and ketorolac tromethamine should not exceed 5 days. Ketorolac tromethamine tablets are not indicated for use in pediatric patients and they are NOT indicated for minor or chronic painful conditions. Increasing the dose of ketorolac tromethamine tablets beyond a daily maximum of 40 mg in adults will not provide better efficacy but will increase the risk of developing serious adverse events. GASTROINTESTINAL RISK Ketorolac tromethamine, including ketorolac tromethamine tablets can cause peptic ulcers, gastrointestinal bleeding and/or perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Therefore, ketorolac tromethamine is CONTRAINDICATED in patients with active peptic ulcer disease, in patients with recent gastrointestinal bleeding or perforation, and in patients with a history of peptic ulcer disease or gastrointestinal bleeding. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS ). CARDIOVASCULAR THOMBOTIC EVENTS Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use (see WARNINGS and PRECAUTIONS ). Ketorolac tromethamine tablets are contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see CONTRAINDICATIONS and WARNINGS ). RENAL RISK Ketorolac tromethamine is CONTRAINDICATED in patients with advanced renal impairment and in patients at risk for renal failure due to volume depletion (see WARNINGS ). RISK OF BLEEDING Ketorolac tromethamine inhibits platelet function and is, therefore, CONTRAINDICATED in patients with suspected or confirmed cerebrovascular bleeding, patients with hemorrhagic diathesis, incomplete hemostasis and those at high risk of bleeding (see WARNINGS and PRECAUTIONS ). Ketorolac tromethamine is CONTRAINDICATED as prophylactic analgesic before any major surgery. RISK DURING LABOR AND DELIVERY The use of ketorolac tromethamine in labor and delivery is contraindicated because it may adversely affect fetal circulation and inhibit uterine contractions. CONCOMITANT USE WITH NSAIDS Ketorolac tromethamine is contraindicated in patients currently receiving aspirin or NSAIDs because of the cumulative risk of inducing serious NSAID-related side effects. SPECIAL POPULATIONS Dosage should be adjusted for patients 65 years or older, for patients under 50 kg (110 lbs) of body weight (see DOSAGE AND ADMINISTRATION ) and for patients with moderately elevated serum creatinine (see WARNINGS ).
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
warnings
Anaphylactoid Reactions As with other NSAIDs, anaphylactoid reactions may occur in patients without a known previous exposure or hypersensitivity to ketorolac tromethamine. Ketorolac tromethamine should not be given to patients with the aspirin triad. This symptom complex typically occurs in asthmatic patients who experience rhinitis with or without nasal polyps, or who exhibit severe, potentially fatal bronchospasm after taking aspirin or other NSAIDs (see CONTRAINDICATIONS and PRECAUTIONS, Preexisting Asthma ). Anaphylactoid reactions, like anaphylaxis, may have a fatal outcome. Emergency help should be sought in cases where an anaphylactoid reaction occurs.
warnings
Cardiovascular Effects Cardiovascular Thrombotic Events Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal. Based on available data, it is unclear that the risk for CV thrombotic events is similar for all NSAIDs.The relative increase in serious CV thrombotic events over baseline conferred by NSAID use appears to be similar in those with and without known CV disease or risk factors for CV disease. However, patients with known CV disease or risk factors had a higher absolute incidence of excess serious CV thrombotic events, due to their increased baseline rate. Some observational studies found that this increased risk of serious CV thrombotic events began as early as the first weeks of treatment. The increase in CV thrombotic risk has been observed most consistently at higher doses. To minimize the potential risk for an adverse CV event in NSAID-treated patients, use the lowest effective dose for the shortest duration possible. Physicians and patients should remain alert for the development of such events, throughout the entire treatment course, even in the absence of previous CV symptoms. Patients should be informed about the symptoms of serious CV events and the steps to take if they occur. There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID, such as ketorolac tromethamine, increases the risk of serious gastrointestinal (GI) events (see WARNINGS ). Status Post Coronary Artery Bypass Graft (CABG) Surgery Two large, controlled clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke. NSAIDs are contraindicated in the setting of CABG (see CONTRAINDICATIONS ). Post-MI Patients Observational studies conducted in the Danish National Registry have demonstrated that patients treated with NSAIDs in the post-MI period were at increased risk of reinfarction, CV-related death, and all-cause mortality beginning in the first week of treatment. In this same cohort, the incidence of death in the first year post MI was 20 per 100 person years in NSAID-treated patients compared to 12 per 100 person years in non-NSAID exposed patients. Although the absolute rate of death declined somewhat after the first year post-MI, the increased relative risk of death in NSAID users persisted over at least the next four years of follow-up. Avoid the use of ketorolac tromethamine tablets in patients with a recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If ketorolac tromethamine tablets are used in patients with a recent MI, monitor patients for signs of cardiac ischemia.
warnings
Hypertension NSAIDs, including ketorolac tromethamine, can lead to onset of new hypertension or worsening of preexisting hypertension, either of which may contribute to the increased incidence of CV events. Patients taking thiazides or loop diuretics may have impaired response to these therapies when taking NSAIDs. NSAIDs, including ketorolac tromethamine, should be used with caution in patients with hypertension. Blood pressure (BP) should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.
warnings
Heart Failure and Edema The Coxib and traditional NSAID Trialists’ Collaboration meta-analysis of randomized controlled trials demonstrated an approximately two-fold increase in hospitalizations for heart failure in COX-2 selective-treated patients and nonselective NSAID-treated patients compared to placebo-treated patients. In a Danish National Registry study of patients with heart failure, NSAID use increased the risk of MI, hospitalization for heart failure, and death. Additionally, fluid retention and edema have been observed in some patients treated with NSAIDs. Use of ketorolac tromethamine may blunt the CV effects of several therapeutic agents used to treat these medical conditions [e.g., diuretics, ACE inhibitors, or angiotensin receptor blockers (ARBs)] (see DRUG INTERACTIONS ). Avoid the use of ketorolac tromethamine tablets in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure. If ketorolac tromethamine tablets are used in patients with severe heart failure, monitor patients for signs of worsening heart failure.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS Adverse reaction rates increase with higher doses of ketorolac tromethamine. Practitioners should be alert for the severe complications of treatment with ketorolac tromethamine, such as GI ulceration, bleeding and perforation, postoperative bleeding, acute renal failure, anaphylactic and anaphylactoid reactions and liver failure (see Boxed WARNING , WARNINGS , PRECAUTIONS , and DOSAGE AND ADMINISTRATION ). These NSAID-related complications can be serious in certain patients for whom ketorolac tromethamine is indicated, especially when the drug is used inappropriately. In patients taking ketorolac tromethamine or other NSAIDs in clinical trials, the most frequently reported adverse experiences in approximately 1% to 10% of patients are: Gastrointestinal (GI) experiences including: abdominal pain Incidence greater than 10% constipation/diarrhea dyspepsia flatulence GI fullness GI ulcers (gastric/duodenal) gross bleeding/perforation heartburn nausea stomatitis vomiting Other experiences: abnormal renal function anemia dizziness drowsiness edema elevated liver enzymes headaches hypertension increased bleeding time injection site pain pruritus purpura rashes tinnitus sweating Additional adverse experiences reported occasionally (<1% in patients taking ketorolac tromethamine or other NSAIDs in clinical trials) include: Body as a Whole: fever, infections, sepsis Cardiovascular: congestive heart failure, palpitation, pallor, tachycardia, syncope Dermatologic: alopecia, photosensitivity, urticaria Gastrointestinal: anorexia, dry mouth, eructation, esophagitis, excessive thirst, gastritis, glossitis, hematemesis, hepatitis, increased appetite, jaundice, melena, rectal bleeding Hemic and Lymphatic: ecchymosis, eosinophilia, epistaxis, leukopenia, thrombocytopenia Metabolic and Nutritional: weight change Nervous System: abnormal dreams, abnormal thinking, anxiety, asthenia, confusion, depression, euphoria, extrapyramidal symptoms, hallucinations, hyperkinesis, inability to concentrate, insomnia, nervousness, paresthesia, somnolence, stupor, tremors, vertigo, malaise Reproductive, female: infertility Respiratory: asthma, cough, dyspnea, pulmonary edema, rhinitis Special Senses: abnormal taste, abnormal vision, blurred vision, hearing loss Urogenital: cystitis, dysuria, hematuria, increased urinary frequency, interstitial nephritis, oliguria/polyuria, proteinuria, renal failure, urinary retention Other rarely observed reactions (reported from postmarketing experience in patients taking ketorolac tromethamine or other NSAIDs) are: Body as a Whole: angioedema, death, hypersensitivity reactions such as anaphylaxis, anaphylactoid reaction, laryngeal edema, tongue edema (see WARNINGS ), myalgia Cardiovascular: arrhythmia, bradycardia, chest pain, flushing, hypotension, myocardial infarction, vasculitis Dermatologic: exfoliative dermatitis, erythema multiforme, Lyells syndrome, bullous reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis Gastrointestinal: acute pancreatitis, liver failure, ulcerative stomatitis, exacerbation of inflammatory bowel disease (ulcerative colitis, Crohns disease) Hemic and Lymphatic: agranulocytosis, aplastic anemia, hemolytic anemia, lymphadenopathy, pancytopenia, postoperative wound hemorrhage (rarely requiring blood transfusion see Boxed WARNING , WARNINGS , and PRECAUTIONS ) Metabolic and Nutritional: hyperglycemia, hyperkalemia, hyponatremia Nervous System: aseptic meningitis, convulsions, coma, psychosis Respiratory: bronchospasm, respiratory depression, pneumonia Special Senses: conjunctivitis Urogenital: flank pain with or without hematuria and/or azotemia, hemolytic uremic syndrome Postmarketing Surveillance Study A large postmarketing observational, nonrandomized study, involving approximately 10,000 patients receiving ketorolac tromethamine IV/IM , demonstrated that the risk of clinically serious gastrointestinal (GI) bleeding was dose-dependent (see Tables 3A and 3B ). This was particularly true in elderly patients who received an average daily dose greater than 60 mg/day of ketorolac tromethamine IV/IM (see Table 3A ). Table 3: Incidence of Clinically Serious GI Bleeding as Related to Age, Total Daily Dose, and History of GI Perforation, Ulcer, Bleeding (PUB) After up to 5 Days of Treatment with Ketorolac Tromethamine IV/IM A. Adult Patients without History of PUB Age of Patients Total Daily Dose of Ketorolac Tromethamine IV/IM ≤60 mg >60 to 90 mg >90 to 120 mg >120 mg <65 years of age 0.4% 0.4% 0.9% 4.6% ≥65 years of age 1.2% 2.8% 2.2% 7.7% B. Adult Patients with History of PUB Age of Patients Total Daily Dose of Ketorolac Tromethamine IV/IM ≤60 mg >60 to 90 mg >90 to 120 mg >120 mg <65 years of age 2.1% 4.6% 7.8% 15.4% ≥65 years of age 4.7% 3.7% 2.8% 25.0% To report SUSPECTED ADVERSE REACTIONS, contact Leading Pharma, LLC at 1-844-740-7500 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
adverse reactions table
<table width="100%" cellspacing="0" cellpadding="5" styleCode="Footnote"> <tbody> <tr> <td valign="top"> <paragraph styleCode="First TableParagraph">abdominal pain <footnote ID="L595ccd15-ce43-4ff3-a6c5-e965f3e086b5">Incidence greater than 10%</footnote> </paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">constipation/diarrhea</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">dyspepsia <footnoteRef IDREF="L595ccd15-ce43-4ff3-a6c5-e965f3e086b5"/> </paragraph> </td> </tr> <tr> <td valign="top"> <paragraph styleCode="First TableParagraph">flatulence</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">GI fullness</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">GI ulcers (gastric/duodenal)</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph styleCode="First TableParagraph">gross bleeding/perforation</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">heartburn</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">nausea <footnoteRef IDREF="L595ccd15-ce43-4ff3-a6c5-e965f3e086b5"/> </paragraph> </td> </tr> <tr> <td valign="top"> <paragraph styleCode="First TableParagraph">stomatitis</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">vomiting</paragraph> </td> <td valign="top"/> </tr> <tr> <td valign="top"> <paragraph styleCode="First TableParagraph">Other experiences:</paragraph> </td> <td valign="top"/> <td valign="top"/> </tr> <tr> <td valign="top"> <paragraph styleCode="First TableParagraph">abnormal renal function</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">anemia</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">dizziness</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph styleCode="First TableParagraph">drowsiness</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">edema</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">elevated liver enzymes</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph styleCode="First TableParagraph">headaches <footnoteRef IDREF="L595ccd15-ce43-4ff3-a6c5-e965f3e086b5"/> </paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">hypertension</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">increased bleeding time</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph styleCode="First TableParagraph">injection site pain</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">pruritus</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">purpura</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph styleCode="First TableParagraph">rashes</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">tinnitus</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">sweating</paragraph> </td> </tr> </tbody> </table>
adverse reactions table
<table width="100%" cellspacing="0" cellpadding="5"> <col width="20%"/> <col width="20%"/> <col width="20%"/> <col width="20%"/> <col width="20%"/> <tbody> <tr> <td rowspan="2" align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">Age of Patients</paragraph> </td> <td colspan="4" align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">Total Daily Dose of Ketorolac Tromethamine <sup>IV/IM</sup> </paragraph> </td> </tr> <tr> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">≤60 mg</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">>60 to 90 mg</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">>90 to 120 mg</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">>120 mg</paragraph> </td> </tr> <tr> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph"><65 years of age</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">0.4%</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">0.4%</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">0.9%</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">4.6%</paragraph> </td> </tr> <tr> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">≥65 years of age</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">1.2%</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">2.8%</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">2.2%</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">7.7%</paragraph> </td> </tr> </tbody> </table>
adverse reactions table
<table width="100%" cellpadding="5"> <col width="20%"/> <col width="20%"/> <col width="20%"/> <col width="20%"/> <col width="20%"/> <tbody> <tr> <td rowspan="2" align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">Age of Patients</paragraph> </td> <td colspan="4" align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">Total Daily Dose of Ketorolac Tromethamine <sup>IV/IM</sup> </paragraph> </td> </tr> <tr> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">≤60 mg</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">>60 to 90 mg</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">>90 to 120 mg</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">>120 mg</paragraph> </td> </tr> <tr> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph"><65 years of age</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">2.1%</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">4.6%</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">7.8%</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">15.4%</paragraph> </td> </tr> <tr> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">≥65 years of age</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">4.7%</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">3.7%</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">2.8%</paragraph> </td> <td align="center" styleCode="Botrule Lrule Rrule" valign="top"> <paragraph styleCode="First TableParagraph">25.0%</paragraph> </td> </tr> </tbody> </table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.